Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
The active ingredient in Ozempic and Wegovy may help reduce the risk of kidney failure in those with Type 2 diabetes and ...
In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...
Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue inflows are assured in the near term. But those ...
Novo Nordisk's Wegovy obesity drug reduced adverse kidney-related events by 22% in overweight and obese people in a large ...
Structure Therapeutics’ American depositary receipts gained more than 6% premarket on Monday after the company said its ...
GLP-1 weight-loss drugs Saxenda and Wegovy stopped taking them within four weeks of use, according to a new study. Read more ...
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...
An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months, according to summary results revealed by developer Structure Therapeutics Monday.
Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death ...
, opens new tab said on Monday its experimental oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations and sending shares 20% higher in ...
Novo Nordisk races against time and high demand to increase supply of Ozempic and Wegovy. There are only two places in the world where semaglutide is made.